)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Scinai Immunotherapeutics
Scinai Immunotherapeutics (SCNI) investor relations material
Scinai Immunotherapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary2 Dec, 2025
Executive summary
Revenue for the nine months ended September 30, 2025, more than doubled year-over-year, driven by CDMO expansion and U.S. subsidiary contributions.
R&D expenses declined significantly due to lower employee and facility allocations.
Net loss of $6.2M versus prior year net profit, reflecting absence of prior year’s one-time financial income from loan conversion.
CDMO business continues to grow, with new grants and investments in advanced manufacturing capabilities.
NanoAbs pipeline advanced, with multiple grant applications and strategic partnering efforts underway.
Financial highlights
Revenue for the nine months ended September 30, 2025: $1.05M, up from $452K year-over-year.
R&D expenses: $1.8M, down from $4.2M year-over-year.
Marketing, general, and administrative expenses: $1.93M, up from $1.77M year-over-year.
Net loss: $6.24M, compared to net profit of $7.03M in the prior year period.
Cash, cash equivalents, and short-term deposits: $3.01M as of September 30, 2025.
Outlook and guidance
Two EU STEP grant decisions (up to €15M each) expected in Q1 2026 for NanoAbs programs.
Installation and qualification of new sterile fill-and-finish system expected in Q1 2026, with commercial operation in Q2 2026.
Strategic assessment ongoing for PC111 program following grant rejection, with options including new grant applications or program termination.
Impact of new fill-and-finish system on CDMO
Status of
30M NanoAbs EU STEP grant applications?
PC111 program's path after grant rejection
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Scinai Immunotherapeutics
- $29M debt swap and regulatory wins drive improved financials and pipeline progress.SCNI
Q2 202423 Jan 2026 - VHH antibodies targeting IL-17A/F show superior local efficacy in psoriasis preclinical models.SCNIStudy Update20 Jan 2026
- Early-stage biopharma/CDMO seeks up to $10M via equity line amid ongoing losses and high risk.SCNIRegistration Filing29 Nov 2025
- Seeking $10M equity to fund NanoAbs and CDMO, with high risk and dilution potential.SCNIRegistration Filing29 Nov 2025
- Biopharma seeks $15M via flexible ADS offering to fund NanoAb pipeline and CDMO growth.SCNIRegistration Filing29 Nov 2025
- Acquisition agreement advances PC111, a novel antibody for rare skin diseases with high market potential.SCNIM&A Announcement26 Nov 2025
- PC111 targets rare skin diseases with high unmet need, offering strong efficacy and billion-dollar potential.SCNIStatus Update26 Nov 2025
- CDMO-driven revenue growth and new financing improved liquidity, but going concern risks persist.SCNIQ2 202511 Sep 2025
- Innovative NanoAb therapies and CDMO services target major unmet needs in dermatology and immunology.SCNICorporate Presentation4 Jul 2025
Next Scinai Immunotherapeutics earnings date
Q4 202511 May, 2026
Scinai Immunotherapeutics
Next Scinai Immunotherapeutics earnings date
Q4 202511 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Scinai Immunotherapeutics Ltd., formerly known as BiondVax Pharmaceuticals Ltd., is an Israeli biopharmaceutical company primarily engaged in the development, manufacture, and commercialization of innovative biological products. The company's focus is on inflammation and immunology, with a particular emphasis on autoimmune and infectious diseases. Scinai's product development pipeline includes a range of nanosized antibodies, known as NanoAbs, derived from alpacas. These antibodies target various diseases with significant unmet medical needs. Additionally, Scinai operates a boutique contract development and manufacturing organization (CDMO) that provides comprehensive services to pharmaceutical, biotech, and alternative protein food tech companies. The company is headquartered in Jerusalem, Israel, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage